REACTIVE: Donor reactive T-cell frequencies in renal transplant recipients: A comparison of the effects of lytic and non-lytic induction therapies
Phase of Trial: Phase II
Latest Information Update: 29 Mar 2007
At a glance
- Drugs Alemtuzumab; Daclizumab
- Indications Renal transplant rejection
- Focus Pharmacodynamics
- 29 Mar 2007 The expected completion date for this trial is now 1 May 2008.
- 29 Mar 2007 New trial record.